Article
Comparing BMD-derived genotoxic potency estimations across variants of the transgenic rodent gene mutation assay.
Environmental and molecular mutagenesis - 1 Dec 2017
Wills John W, Johnson George E, Battaion Hannah L, Slob Wout, White Paul A
Abstract excerpt
There is growing interest in quantitative analysis of in vivo genetic toxicity dose-response data, and use of point-of-departure (PoD) metrics such as the benchmark dose (BMD) for human health risk assessment (HHRA). Currently, multiple transgenic rodent (TGR) assay variants, employing different rodent strains and reporter transgenes, are used for the assessment of chemically-induced genotoxic effects in vivo....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.